American Century Companies Inc. Sells 532,674 Shares of Zimmer Biomet Holdings, Inc. $ZBH

American Century Companies Inc. cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,176,696 shares of the medical equipment provider’s stock after selling 532,674 shares during the quarter. American Century Companies Inc. owned about 2.61% of Zimmer Biomet worth $509,905,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ZBH. Key Financial Inc lifted its holdings in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. grew its holdings in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its position in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC bought a new stake in Zimmer Biomet in the third quarter worth about $31,000. Finally, Mather Group LLC. purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $36,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

ZBH stock opened at $98.42 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The firm has a market cap of $19.25 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 2.06 and a beta of 0.62. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The firm has a 50-day simple moving average of $91.52 and a two-hundred day simple moving average of $95.95.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Analyst Upgrades and Downgrades

ZBH has been the topic of several recent analyst reports. Johnson Rice set a $112.00 price target on Zimmer Biomet in a report on Wednesday, November 5th. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a research note on Wednesday, November 5th. William Blair started coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. Finally, Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.